Blueprint Medicines (United States)
- World rank, all time
- #15,079 of 42,892
- Rank in United States
- #3,297 of 8,685
- Research works
- 199 ▲ 94% vs 2013–17
- Citations
- 8.5k 42.7 per fractional work
- Top-10% rate
- 11.6% record average 16.5%
- Open access
- 67% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 15.6×. Every wedge is a field page.
- Immunology and Microbiology 15.6×
- Pharmacology, Toxicology and Pharmaceutics 3.5×
- Medicine 2.7×
- Decision Sciences 2.5×
- Biochemistry, Genetics and Molecular Biology 2.3×
- Chemistry 1.7×
- Veterinary 0.9×
- Health Professions 0.7×
- Psychology 0.6×
- Earth and Planetary Sciences 0.4×
- Environmental Science 0.3×
- Engineering 0.2×
- Arts and Humanities 0.2×
- Economics, Econometrics and Finance 0.2×
- Social Sciences 0.2×
- Nursing 0.2×
- Computer Science 0.1×
- Mathematics 0.1×
- Agricultural and Biological Sciences 0.1×
- Business, Management and Accounting 0.0×
- Neuroscience 0.0×
- Materials Science 0.0×
Who are the top researchers at Blueprint Medicines (United States)?
Ranked on the composite score, Klaus P. Hoeflich, Erin Sullivan and Flemming Bust lead among researchers whose main affiliation is Blueprint Medicines (United States).
- 1 Klaus P. Hoeflich United States · #1,051,280 worldwide 24 citations · 19 works
- 2 Erin Sullivan United States · #1,113,691 worldwide 15 citations · 19 works
- 3 Flemming Bust United States · #1,628,827 worldwide 0 citations · 19 works
Which keywords describe research at Blueprint Medicines (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Inflammation, Immune Responses, Allergic Disease, Mast Cells, Clinical Trials, Chemotherapy, Targeted Therapy and Asthma.
- Topoisomerases
- DNA
- Genomic Stability
- Imatinib Mesylate
- Genomic Profiles
- ALK Inhibitors
- Urticaria
- Biomarkers
- Autoantibodies
- Management
- Diagnosis
- CDK4/6 Inhibitors
- Immunotherapy
- Metastatic Breast Cancer
- Eosinophils
- Targeted Therapy
- Treatment
- Epidemiology
- Mast Cells
- Allergic Disease
- Inflammation
- Immune Responses
- Clinical Trials
- Chemotherapy
- Asthma
- Allergic Diseases
- Quality of Life
- Breast Cancer
- Prognostic Factors
- Palbociclib
- Metastasis
- Treatment Guidelines
- Autoimmune
- Chronic Spontaneous Urticaria
- Cancer Therapy
- EGFR Mutations
- Small-Cell Lung Cancer
- Translational Research
- Inhibitors
- Patient Safety
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Inflammation12▲ 9.9×10 topics
- Allergic Disease8▲ 918×1 topic
- Immune Responses8▲ 96×2 topics
- Mast Cells8▲ 918×1 topic
- Clinical Trials5▲ 13×6 topics
- Epidemiology5▲ 2.1×12 topics
- Chemotherapy5▲ 11×9 topics
- Treatment4▲ 6.1×8 topics
- Asthma4▲ 71×3 topics
- Targeted Therapy4▲ 31×4 topics
- Allergic Diseases4▲ 110×1 topic
- Eosinophils4▲ 110×1 topic
- Quality of Life4▲ 4.6×6 topics
- Metastatic Breast Cancer4▲ 112×2 topics
- Breast Cancer4▲ 26×4 topics
- Immunotherapy4▲ 8.4×11 topics
- Prognostic Factors3▲ 13×9 topics
- CDK4/6 Inhibitors3▲ 208×1 topic
- Palbociclib3▲ 208×1 topic
- Diagnosis3▲ 5.3×8 topics
- Metastasis3▲ 13×4 topics
- Management2▲ 5.4×4 topics
- Treatment Guidelines2▲ 19×2 topics
- Autoantibodies2▲ 17×2 topics
- Autoimmune2▲ 84×2 topics
- Biomarkers2▲ 5.5×6 topics
- Chronic Spontaneous Urticaria2▲ 172×1 topic
- Urticaria2▲ 172×1 topic
- Cancer Therapy2▲ 6.2×7 topics
- ALK Inhibitors2▲ 53×1 topic
- EGFR Mutations2▲ 53×1 topic
- Genomic Profiles2▲ 68×1 topic
- Small-Cell Lung Cancer2▲ 68×1 topic
- Imatinib Mesylate1▲ 45×2 topics
- Translational Research1▲ 64×2 topics
- Genomic Stability1▲ 58×2 topics
- Inhibitors1▲ 53×2 topics
- DNA1▲ 117×1 topic
- Patient Safety1▲ 13×2 topics
- Topoisomerases1▲ 117×1 topic
Which research topics does Blueprint Medicines (United States) publish most on?
By volume in 2022–2025: Mast cells and histamine, Asthma and respiratory diseases, Advanced Breast Cancer Therapies and Urticaria and Related Conditions.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Mast cells and histamine Immunology 8 works
- 2 Asthma and respiratory diseases Physiology 4 works
- 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 3 works
- 4 Urticaria and Related Conditions Rheumatology 2 works
- 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 6 Lung Cancer Research Studies Oncology 2 works
- 7 Cancer therapeutics and mechanisms Molecular Biology 1 works
- 8 Eosinophilic Disorders and Syndromes Rheumatology 1 works
- 9 Veterinary Practice and Education Studies Speech and Hearing 1 works
- 10 Cancer-related Molecular Pathways Oncology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Blueprint Medicines (United States)'s research output changed?
Output in 2018–2022 was 94% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Cambridge
- Harvard University
- Massachusetts Institute of Technology
- Center for Astrophysics Harvard & Smithsonian
- National Bureau of Economic Research
- IIT@MIT
- World Wide Web Consortium
- Broad Institute
- Smithsonian Astrophysical Observatory
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.